And the winner is …. cancer research
The three winners of the first Roche Pharma Research & Development (pRED) Oncology awards in the field of ‘Novel Highly tumour-selective Membrane Targets for Antibody-based cancer Therapy’ have been selected.
Jury mit stolzen Preisträgern; von links: Christian Jost (2. Preis), Prof. Gerhard Niederfellner, Klaus Bosslet, Krishna Chaitanya (1. Preis), Prof. Hans-Peter Altevogt, Vineeta Bhasker Tripathi (3. Preis), Prof. Winfried Welz
Roche Diagnostics
Krishna Chaitanya of the Oncological Institute at the University Hospital Zurich received the first prize for his outstanding studies on a radioisotope-coupled antibody against fibroblast activation protein (FAP), which provide a new approach to attacking tumor stroma. Tumor stroma consists of cells which support the growth of tumors. The 2nd prize went to Christian Jost of the Institute of Biochemistry at the University of Zurich for a completely novel concept enabling the inactivation of the HER2 receptor with small, non-antibody based binding molecules. Vineeta Bhasker Tripathi from the UCL Institute of Ophthalmology in London received the 3rd prize for her studies on the validation of Lrg 1 (leucine-rich alpha-2-glycoprotein-1) as a new target molecule for the suppression of blood vessel formation in tumors with the aid of function-inhibiting antibodies.
"We are delighted by the outstanding quality and great number of submissions on this vital cancer research topic,” commented Klaus Bosslet, Head of Discovery Oncology, and initiator of the award. “For the first award of a prize, this is an extraordinary result.”
Other news from the department science
